Argentina
Tuberculosis profile
Population  2013 41 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.57 (0.54–0.59) 1.4 (1.3–1.4)
Mortality (HIV+TB only) 0.044 (0.012–0.096) 0.11 (0.03–0.23)
Prevalence  (includes HIV+TB) 13 (5.6–23) 31 (14–56)
Incidence  (includes HIV+TB) 10 (9.1–12) 24 (22–28)
Incidence (HIV+TB only) 0.27 (0.25–0.61) 0.65 (0.61–1.5)
Case detection, all forms (%) 89 (78–98)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.2–3.6) 15 (9.8–23)
MDR-TB cases among notified pulmonary
TB cases
160 (87–260) 200 (130–300)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 5 223   357
Pulmonary, clinically diagnosed 2 054   74
Extrapulmonary 1 188   37
       
Total new and relapse 8 933    
Previously treated, excluding relapses 881    
Total cases notified 9 814    
Among 8 933 new and relapse cases:
893 (10%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 429 (27%) 728 (54%) 3 157
Laboratory-confirmed RR-/MDR-TB cases     85
Patients started on MDR-TB treatment      
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 720 (18)
HIV-positive TB patients 775 (45)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 56
Previously treated cases, excluding relapse, registered in 2012 44
HIV-positive TB cases, all types, registered in 2012 24
RR-/MDR-TB cases started on second-line treatment in 2011 28
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.7
Culture (per 5 million population) 18.2
Drug susceptibility testing (per 5 million population) 2.1
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 2.4
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-29 Data: www.who.int/tb/data